Cytomed Therapeutics Ltd key statistics and ratios

In fiscal 2025, Cytomed Therapeutics Ltd had return on equity of -52.3%, a net margin of -1227.1%, debt equal to 6.3% of equity and a current ratio of 5.17. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Cytomed Therapeutics Ltd: financial ratios, annual
Fiscal year	2024Dec 2024	2025Dec 2025
Net margin	<−999%	<−999%
Free-cash-flow margin	<−999%	<−999%
Return on equity	−28.7%	−52.3%
Return on assets	−25.6%	−44.9%
Asset turnover	0.01	0.04
Current ratio	9.89	5.17
Debt to equity	4.8%	6.3%
R&D as % of revenue	>999%	683.6%
Capital spending as % of revenue	>999%	196.6%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

4 of 5 checks passed · December 31, 2025

What it owns · $6m

Short-term assets $3mLonger-term assets $3m

What it owes, and who funded it · $6m

Short-term liabilities $1mLonger-term liabilities $0mShareholders' equity $5m

Short-term assets cover short-term liabilities $3m of assets due within a year against $551,496 of liabilities due within a year.
Short-term assets cover long-term liabilities $3m short-term assets against $328,266 of longer-dated liabilities.
More cash than debt $2m of cash against $318,456 of debt.
Debt below 40% of shareholders' equity Debt is 6% of equity.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt −$3m of operating cash flow against $318,456 of debt.
Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Cytomed Therapeutics Ltd's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: CLNN vs GDTC CRVO vs GDTC CLDX vs GDTC

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Cytomed Therapeutics Ltd's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cytomed Therapeutics Ltd.